China International Capital Corporation Limited's Review Opinion on Beijing Remeet Medical Technology Co., Ltd.'s Use of Idle Own Funds for Entrusted Wealth Management

China International Capital Corporation Limited (hereinafter referred to as "CICC" or "Sponsor"), as the sponsor of Beijing Remeet Medical Technology Co., Ltd. (hereinafter referred to as "Remeet" or "the Company") for its initial public offering and continuous supervision, has reviewed the matter of the Company using idle own funds for entrusted wealth management in accordance with the "Administrative Measures for Securities Issuance and Listing Sponsorship Business," the "Shenzhen Stock Exchange GEM Stock Listing Rules," the "Shenzhen Stock Exchange Listed Company Self-Regulatory Management Guidelines No. 2 - Norms for the Operation of GEM Listed Companies," and other relevant laws, regulations, departmental rules, and business rules. The details are as follows:

I. Situation of Using Idle Own Funds for Entrusted Wealth Management

1. Investment Objective: To enhance fund utilization efficiency, while ensuring the Company's daily capital needs and capital security, and based on actual operating conditions, the Company plans to use idle own funds for entrusted wealth management to increase investment returns and obtain better investment returns for the Company and its shareholders.

2. Investment Products: Within the aforementioned quota, the Company intends to purchase wealth management products, income certificates, reverse repurchase agreements, asset management products, and trust plans issued by financial institutions such as banks, securities companies, trust companies, fund management companies, and asset management companies, for flexible allocation and investment in risk-controllable wealth management products.

3. Investment Quota and Term: This time, the Company plans to use no more than RMB 950 million (inclusive) of idle own funds for entrusted wealth management. The fund quota is valid from the date of approval by the Company's 2025 annual board of directors meeting to the date of the Company's 2026 annual board of directors meeting. Within this quota and validity period, funds can be used in a revolving manner.